Mesoblast Limited (NASDAQ:MESO) Sees Large Growth in Short Interest

Mesoblast Limited (NASDAQ:MESO - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 2,340,000 shares, a growth of 190.1% from the March 15th total of 806,500 shares. Based on an average trading volume of 2,140,000 shares, the days-to-cover ratio is presently 1.1 days.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on MESO shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a research note on Friday, January 12th. StockNews.com cut shares of Mesoblast from a "hold" rating to a "sell" rating in a research note on Tuesday, April 2nd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Mesoblast presently has an average rating of "Hold" and an average target price of $13.67.

Mesoblast Stock Down 1.2 %

MESO stock traded down $0.07 during mid-day trading on Thursday, hitting $5.73. The company had a trading volume of 393,631 shares, compared to its average volume of 2,006,526. The company has a 50-day moving average price of $2.99 and a 200 day moving average price of $2.50. Mesoblast has a 12-month low of $1.61 and a 12-month high of $10.24. The company has a market capitalization of $653.63 million, a price-to-earnings ratio of -5.12 and a beta of 3.60.

Institutional Trading of Mesoblast

A number of large investors have recently made changes to their positions in the business. Lazari Capital Management Inc. increased its holdings in shares of Mesoblast by 9.3% in the 3rd quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company's stock worth $116,000 after buying an additional 8,000 shares during the last quarter. Prosperity Wealth Management Inc. bought a new stake in shares of Mesoblast in the 3rd quarter worth about $79,000. Wells Fargo & Company MN increased its holdings in shares of Mesoblast by 55.0% in the 2nd quarter. Wells Fargo & Company MN now owns 52,813 shares of the company's stock worth $206,000 after buying an additional 18,747 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Mesoblast by 68.6% in the 2nd quarter. BlackRock Inc. now owns 140,716 shares of the company's stock worth $550,000 after buying an additional 57,252 shares during the last quarter. Finally, EWA LLC bought a new stake in shares of Mesoblast in the 1st quarter worth about $40,000. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.